Justices Urged To Reject Review Of Biogen MS Drug IP Ruling
Mylan said Monday the U.S. Supreme Court should skip reviewing a Federal Circuit decision that affirmed the invalidation of a Biogen patent on the blockbuster multiple sclerosis drug Tecfidera, saying a...To view the full article, register now.
Already a subscriber? Click here to view full article